Autres langues Tourmaline Bio, Inc.

Actions

TRML

US89157D1054

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
16 ^USD	+3,83 %		+2,17 %	-38,88 %

21/03	Wall Street s'apprête à ouvrir en hausse après le maintien des taux d'intérêt par la Fed ; les demandes initiales d'allocations chômage sont inférieures aux prévisions	MT
21/03	Les contrats à terme américains tendent à la hausse après la décision de la Fed de maintenir les taux d'intérêt inchangés	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	21/03
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	21/03
Top Premarket Decliners	21/03
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	19/03
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	19/03
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	31/01
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	29/01
Tourmaline Bio Prices $150 Million Common Stock Offering	25/01
Tourmaline Bio Announces Pricing of Public Offering of Common Stock	25/01
Tourmaline Bio Announces Proposed Public Offering of Common Stock	24/01
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)	08/01
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index	18/12
Tourmaline Bio Joins Nasdaq Biotechnology Index	15/12
Tourmaline Bio added to the NASDAQ Biotechnology Index	15/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tourmaline Bio, Inc.

Actions

TRML

US89157D1054

Autres langues

Filtres